Octavio Rodrigues, dr. med., spec. nevr.
Dr. Octavio Rodríguez‐Gómez. Born in Lugo, Spain (1982). He graduated in Medicine and Surgery in 2006 from the University of Santiago de Compostela. He got his training in Neurology in Hospital Clínico San Carlos (Madrid) between 2008 and 2012. He began his work at Fundació ACE in 2012, where he is combining clinical work in the diagnosis and treatment of people with cognitive impairment and research activity. He has been involved as a subinvestigator in more than 30 clinical trials for the treatment of Alzheimer´s disease. He is in charge of the coordination of the FACEHBI study, a longitudinal study in a cohort of individuals with subjective cognitive decline. He is also involved in the coordination of MOPEAD, a multi‐centric European study focused on patient engagement strategies (www.imi‐mopead.eu). His scientific interest is focused on the early diagnosis and prevention of AD, paying special attention to the study of preclinical AD and subjective cognitive decline. He is in charge of the recruitment of clinical trials for preclinical AD. Rodríguez is coordinating Fundació ACE´s strategy on patient engagement, preclinical diagnosis and prevention of dementia.
The FACEHBI Study
The disappointing results of clinical trials in people with Alzheimer´s disease (AD) dementia have highlighted the necessity to act earlier. Growing scientific evidence supports the idea that the biological events underlying AD begin years or even decades before the symptom onset, leading to the formulation of a new entity: preclinical AD. Preclinical AD can be seen as an opportunity to treat Alzheimer´s disease in the moment in which the therapies are supposed to be potentially more effective. The diagnosis of preclinical AD entirely relies in the positivity of specific biomarkers not issued to be applied to big populations because they are usually expensive and not completely innocuous. For this reason we need new harmless and easy to implement strategies to predict which individuals could be more likely to be biomarker positive. There is evidence that subjective cognitive decline SCD is associated with AD biomarkers and increases the risk of future cognitive impairment. Thus, including people with SCD in a cohort of individuals without objective cognitive impairment could be a cost‐effective strategy to increase the prevalence of preclinical AD.
FACEHBI is a longitudinal observational study carried out in individuals with SCD. Our objectives are to better delineate the biological and psychological phenomena involved in preclinical AD as well as the value of SCD as a predictor of cognitive impairment.
200 individuals older than 49 years without cognitive impairment diagnosed with SCD in Fundació ACE (Barcelona) have been recruited for the FACEHBI study. The FACEHBI protocol includes a set of multimodal biomarkers, combined with a very comprehensive neuropsychological assessment. Lifestyle risk factors, personality traits and social environment are carefully assessed as well. The different assessments will be repeated at yearly follow up visits.
The recruitment and the first follow up have been completed for all the participants. The mean age is 65 years old and 70% of the participants are women
SCD can be understood as an opportunity to identify individuals at high risk of developing cognitive impairment. FACEHBI is an ambitious longitudinal project intended to study risk factors, multimodal biomarkers and cognition in a sample of individuals with SCD.